A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN
argenx · NCT07773727
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Phase 2
- Target enrollment
- 120
- US sites recruiting
- 8
- Study start
- November 5, 2026
- Record last updated
- October 27, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The study will assess how ARGX-121 affects immunoglobulin A nephropathy (IgAN) disease outcomes, such as renal function, how it is distributed and eliminated from the body, and how the immune system responds in adults with IgAN.
While in the study, participants will continue to receive their usual medical care and medications for IgA nephropathy, unless the study doctor confirms otherwise.
The study will include a double blinded period, followed by an active drug period, and conclude with a follow up period. The total study duration for participants will be approximately 72 weeks, with a maximum of 52 weeks on ARGX-121.
Being studied: ARGX-121; Placebo
Conditions: Immunoglobulin A Nephropathy (IgAN)
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Males and females (not pregnant)
- At least 18 years old
- Clinically diagnosed with IgAN with biopsy confirmation
Exclusion Criteria
- Diagnosis of another autoimmune disease or known medical condition that would interfere with accurate assessment of clinical systems of IgAN
- Has secondary form of IgAN leading to IgA deposits
- History of Malignancy
- Active infection of concern
- Recent Major surgery or organ transplant
Recruiting US locations
Amicis Research Center - Valencia
Valencia, CA 91355
Site contact: 857-350-4834 · clinicaltrials@argenx.com
Bioresearch Partners
Miami, FL 33127
Site contact: +1 857-350-4834 · clinicaltrials@argenx.com
Nephrology Associates of South Miami PA
Miami, FL 33173-3456
Site contact: +1 857-350-4834 · clinicaltrials@argenx.com
BioResearch Partner - Pembroke Pines
Pembroke Pines, FL 33029
Site contact: 857-350-4834 · clinicaltrials@argenx.com
Michigan Kidney Consultants
Pontiac, MI 48341
Site contact: +1 857-350-4834 · clinicaltrials@argenx.com
Prolato Clinical Research Center
Houston, TX 77054
Site contact: 857-350-4834 · clinicaltrials@argenx.com
Utah Kidney Research Institute
Salt Lake City, UT 84115
Site contact: 857-350-4834 · clinicaltrials@argenx.com
Kidney and Hypertension Specialists- Virginia
Manassas, VA 20110
Site contact: +1 857-350-4834 · clinicaltrials@argenx.com
Study contacts (from the official record)
- Sabine Coppieters, MD · 857-350-4834 · Clinicaltrials@argenx.com